Asia Pacific RNAi Therapeutics Market Analysis and Opportunities by 2027

Historic Data: 2017-2018 | Base Year: 2019 | Forecast Period: 2020-2027

Asia Pacific RNAi Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Molecule Type (Small Interfering RNAs (siRNA) and MicroRNA (miRNA)), Application (Genetic Disorders, Oncology, Neurodegenerative Disorders, Cardiovascular, Respiratory Disorders, Infectious Diseases, Renal Diseases, and Others), Route of Administration (Intradermal Injections, Pulmonary Delivery, Intravenous Injections, Intraperitoneal Injections, and Others), and End User (Diagnostic Laboratories, Research and Academic Laboratories, and Hospitals) and Geography

Report Date : Oct 2020
Report Code : TIPRE00015147

Category : Life Sciences
Status : Published

Available Report Formats :
No. of Pages : 133

Page Updated: Oct 2020

Analysis Strategic Insights Market Drivers Regional Insights Report Scope Recent Developments FAQs

The Asia Pacific RNAi therapeutics market is expected to reach US$ 218.64 million by 2027 from US$ 107.63 million in 2019. The market is estimated to grow at a CAGR of 9.3% from 2020 to 2027.

Growing investments in RNAi therapies and rising prevalence of infectious diseases & chronic conditions in Asia Pacific are the key factors driving the growth of RNAi therapeutics. However, high cost of RNAi therapies is the major factor hindering the market growth in Asia Pacific.

RNAi refers to the interference RNA which is responsible to control and manipulate protein translation in the cell. These RNAi are used to silence particular genes which are responsible for diseases. Currently, the awareness about RNAi is increasing extensively due to its ability to offer target specific mechanism, leading to superior treatment outcomes. The approach is widely utilized for drug development. Increasing number of investments in RNAi therapy development coupled with growing prevalence of infectious diseases and chronic conditions are anticipated to drive the Asia Pacific RNAi Therapeutics market during the forecast period.

Continuous R&D activities in RNAi therapeutics have revealed its benefits in tackling a range of chronic disorders, such as genetic conditions, renal disorders, neurodegenerative conditions, and oncology. The effectiveness of outcomes of RNAi therapies is generating investments in the development of new drugs. For instance, in June 2020, OliX Pharmaceuticals signed an agreement with LGC Biosearch technologies to accelerate production of asymmetric siRNA for the treatment of sub-retinal fibrosis and wet macular degeneration. Also, NantVentures made a private investment in public Australia based biotech Benitec Biopharma. Furthermore, Benitech and NantVentures, with the help of NantWorks, plan to begin an oncology-focused R&D collaboration with clinical development and preclinical evaluation that is to be led by Benitec. Moreover, in July 2018, Axovant Sciences signed a gene therapy licensing and development deal with Benitec Biopharma. As part of the deal, Axovant Sciences made an upfront payment of US$ 10 million to Benitec, which is also eligible for additional payments based on regulatory, development, and commercial sales milestones. Such investments help biotech and pharma companies not only launch new products but also increase number of approved products. The market players are gaining investments in the R&D of new drugs, therapies, and technologies. These increasing investments in RNAi therapeutics are driving the growth of the market.

Countries in Asia Pacific are severely affected by the COVID-19 outbreak. Several companies operating in this region are developing therapies for COVID-19. South Korea based OliX Pharmaceuticals, Inc., a leading developer of RNA interference (RNAi), announced that it would leverage previous preclinical research for developing siRNA therapeutics in treating respiratory illnesses to investigate a path forward for developing a COVID-19 therapy. Such continuous developments of RNAi therapies in Asia Pacific are likely to propel the market growth in this region.

Rest of Asia Pacific RNAi Therapeutics Market, Revenue, and Forecast to 2027 (US$ Million)

This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Asia Pacific RNAi Therapeutics Market Segmentation

By Molecule Type

Small Interfering RNAs (siRNA)
MicroRNA (miRNA)

By Route of Administration

Pulmonary Delivery
Intravenous Injections
Intradermal Injections
Intraperitoneal Injections
Others

By Application

Oncology
Cardiovascular
Respiratory Disorders
Renal Diseases
Genetic Disorders
Neurodegenerative Disorders
Infectious Diseases
Others

By End User

Research and Academic Laboratories
Hospitals
Diagnostic Laboratories

By Country

Japan
China
India
South Korea
Australia

Company Profiles

Benitec Biopharma
GlaxoSmithKline plc
Olix Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.

Asia Pacific RNAi Therapeutics Report Scope

Report Attribute	Details
Market size in 2019	US$ 107.63 Million
Market Size by 2027	US$ 218.64 Million
Global CAGR (2020 - 2027)	9.3%
Historical Data	2017-2018
Forecast period	2020-2027
Segments Covered	By Molecule Type Small Interfering RNAs MicroRNA By Application Genetic Disorders Oncology Neurodegenerative Disorders Cardiovascular Respiratory Disorders Infectious Diseases Renal Diseases By Route of Administration Intradermal Injections Pulmonary Delivery Intravenous Injections Intraperitoneal Injections By End User Diagnostic Laboratories Research and Academic Laboratories Hospitals
Regions and Countries Covered	Asia-Pacific China India Japan Australia Rest of Asia-Pacific
Market leaders and key company profiles	Benitec Biopharma Olix Pharmaceuticals, Inc. GlaxoSmithKline plc Alnylam Pharmaceuticals, Inc. Arrowhead Pharmaceuticals, Inc

Research Manager

Mrinal Kerhalkar

Manager,
Market Research & Consulting

Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

What are the Asia Pacific RNAi Therapeutics Market report deliverables?

Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
PEST and SWOT Analysis
Market Size Value / Volume - Global, Regional, Country
Industry and Competitive Landscape
Excel Dataset

Recent Reports

Testimonials

I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.

DR CHIJIOKE ONYIA MANAGING DIRECTOR, PineCrest Healthcare Ltd.

The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services

YUKIHIKO ADACHI CEO, Deep Blue, LLC.

We worked with The Insight Partners for an important market study and forecast. They gave us clear insights into opportunities and risks, which helped shape our plans. Their research was easy to use and based on solid data. It helped us make smart, confident decisions. We highly recommend them.

PIYUSH NAGPAL Sr. Vice President, High Beam Global

I requested a report on a very specific software market and the team produced the report in a few days. The information was very relevant and well presented. I then requested some changes and additions to the report. The team was again very responsive and I got the final report in less than a week.

Jean-Herve Jenn Chairman, Future Analytica

This is the first time I have purchased a market report from The Insight Partners.While I was unsure at first, I visited their web site and felt more comfortable to take the risk and purchase a market report.I am completely satisfied with the quality of the report and customer service. I had several questions and comments with the initial report, but after a couple of dialogs over email with their analyst I believe I have a report that I can use as input to our strategic planning process.Thank you so much for taking the extra time and making this a positive experience.I will definitely recommend your service to others and you will be my first call when we need further market data.

John Suzuki President and Chief Executive Officer, Board Director, BK Technologies

The Insight Partners' SCADA System Market report is comprehensive, with valuable insights on current trends and future forecasts. The team was highly professional, responsive, and supportive throughout. We are very satisfied and highly recommend their services.

Ran Kedem Partner, Reali Technologies LTDs

Reason to Buy